Targeting the immune response to treat Ewing Sarcoma
Attacking the Immunopeptidome of Ewing Sarcoma
['FUNDING_U01'] · STANFORD UNIVERSITY · NIH-10927350
This study is exploring new treatments for Ewing Sarcoma, a type of bone cancer that mainly affects kids and young adults, by using the immune system to help it recognize and fight the cancer cells more effectively.
Quick facts
| Phase | ['FUNDING_U01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | STANFORD UNIVERSITY (nih funded) |
| Locations | 1 site (STANFORD, UNITED STATES) |
| Trial ID | NIH-10927350 on ClinicalTrials.gov |
What this research studies
This research investigates new ways to treat Ewing Sarcoma, a type of bone cancer that primarily affects children and young adults. It focuses on harnessing the immune system to recognize and attack cancer cells by identifying specific proteins that are overexpressed in Ewing Sarcoma but not found in healthy tissues. The approach involves using advanced techniques to profile the immune response and develop targeted therapies that can overcome the body's natural tolerance to these proteins. By utilizing immunotherapy, the goal is to improve treatment outcomes for patients with this challenging cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research include children and young adults diagnosed with Ewing Sarcoma, particularly those with metastatic or recurrent disease.
Not a fit: Patients with Ewing Sarcoma who do not express the specific proteins targeted by this research may not benefit from these therapies.
Why it matters
Potential benefit: If successful, this research could lead to more effective and targeted treatments for Ewing Sarcoma, potentially improving survival rates and reducing long-term side effects for patients.
How similar studies have performed: Previous research has shown promise in using immunotherapy approaches for other cancers, but this specific application to Ewing Sarcoma is novel and untested.
Where this research is happening
STANFORD, UNITED STATES
- STANFORD UNIVERSITY — STANFORD, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MACKALL, CRYSTAL — STANFORD UNIVERSITY
- Study coordinator: MACKALL, CRYSTAL
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.